Navigation Links
ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013
Date:4/25/2013

EXTON, Pa., April 25, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2013 are expected to be released on Wednesday, May 1, 2013 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2013 first quarter financial results, review clinical data and provide development program updates along with other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until May 15, 2013.  To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call. 

About ViroPharma Incorporated 
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
2. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
3. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
4. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
5. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
6. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
7. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
8. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
9. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
10. ViroPharma To Participate In The JMP Securities Healthcare Conference
11. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 A case report and ... SynCardia temporary Total Artificial Heart into a patient with ... were reversed, along with other abnormalities. ... the SynCardia Total Artificial Heart to treat a patient ... and video in the Journal of Visualized Experiments show ...
(Date:9/23/2014)... Sept. 23, 2014  Savant HWP, Inc., a ... initiation of human safety testing of 18-MC, an ... single dose of 18-MC, administered as part of ... Savant,s South American partner, was well tolerated by ... plans to develop 18-MC as a treatment for ...
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
Breaking Medicine Technology:1st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7
... -- Weikang Bio-technology Group, Inc. (the "Company," "Weikang" or ... all of its management departments into the building it ... Chengde Street in the Daowai District of Harbin, the ... of the building. Mr. Yin Wang, the ...
... Dec. 27, 2011  PharmacoFore, Inc., a privately held biopharmaceutical ... equity financing from Founders Fund and the addition ... Board of Directors.   PharmacoFore uses innovative ... treating a variety of conditions related to the ...
Cached Medicine Technology:Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 2Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 3PharmacoFore, Inc. Secures $10 Million in Equity Financing From Founders Fund 2
(Date:9/23/2014)... What: Rutgers Presbyterian Church, a ... that embodies the inclusion and diversity of New ... the Ecological Crisis, a public lecture led by ... of Old Testament at Louisville Presbyterian Seminary. Tull ... lends insight into current ecological problems, including energy ...
(Date:9/23/2014)... teenagers could grow up to earn up to 18 ... says Petter Lundborg of Lund University, Paul Nystedt of ... Lund University, all in Sweden. The team compared extensive ... States, and the results are published in Springer,s journal ... data of 145,193 Swedish-born brothers who enlisted in the ...
(Date:9/23/2014)... 2014 Trevera provides multiple lines ... are Oracle Managed Services , Oracle Solutions ... versions of Oracle E-Business Databases and Applications, ... Trevera has announced a significant enhancement to its ... with their software technology management, project management, governance, ...
(Date:9/23/2014)... Greensboro, NC (PRWEB) September 23, 2014 ... (UNCG), a national research university located In the ... has joined UNCG as co-director of the Center ... in bioanalytical chemistry, comes to UNCG after nearly ... Pacific Northwest National Laboratory, Biological Sciences Division. ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... for a hemorrhagic stroke -- which causes bleeding in the ... survive than people who weren,t taking the drugs, according to ... known as statins were also 2.5 times more likely to ... reports. When it comes to the best treatment for ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Note to young men: Fat doesn't pay 2Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3
... why some of the bacteria that cause stomach ulcers ... cancer than others; it turns out these bacteria can ... the immune system. , Helicobacter pylori is a bacterial ... inflammation, ulcers, and potentially even stomach cancer. However, only ...
... LOUIS, Aug. 22 CMS, Inc., an Elekta ... workflow management,solutions, has received FDA 510(k) clearance for ... CMS to immediately,begin distributing Atlas-Based Autosegmentation for clinical ... amount of time spent creating and editing,patient contours, ...
... to launch the most sophisticated mission ever to investigate ... shape of our planet the geoid - with ... steady-state Ocean Circulation Explorer (GOCE) will be placed onto ... Rockot vehicle launched from the Plesetsk Cosmodrome in Northern ...
... But the agency says patients can still take ... News) -- U.S. drug regulators said Thursday that ... might be linked to cancer. , The U.S. ... health-care professionals that the agency was investigating a ...
... to its superior service, ... and innovative technology, FORT WORTH, Texas, Aug. 22 ... services to the retail pharmacy,industry, today announced that it ... editing and reporting services business,partner. eRx Network,s suite of ...
... halide compounds, American Elements announced today it has increased the capacity ... , ... Los Angeles, CA (PRWEB) August 22, 2008 -- ... today it has increased the capacity for U.S. based manufacturing of ...
Cached Medicine News:Health News:CMS, Inc., an Elekta Company, Receives FDA 510(k) Clearance for Atlas-Based Autosegmentation Software 2Health News:GOCE Earth explorer satellite to look at the Earth's surface and core 2Health News:FDA Investigates Possible Vytorin-Cancer Link 2Health News:FDA Investigates Possible Vytorin-Cancer Link 3Health News:Kmart Pharmacy Awards Its Transaction Processing Business to eRx Network 2
... Eliminate aerosol contamination, which ... in PCR. Hydrophobic, nonwicking ... air can pass through ... in contrast to tips ...
... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
Medicine Products: